Trial Profile

AtheroSclerotic Cardiovascular disEase Risk assessmenT and treAtment In AustraliaN Primary Care (VICTORION-ASCERTAIN: Implementation Study)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inclisiran (Primary)
Indications Cardiovascular disorders; Coronary artery disease
Focus Therapeutic Use
Acronyms ASCERTAIN; v-ASCERTAIN

Most Recent Events

27 Jan 2025 Status changed from recruiting to discontinued. (Reason the study was stopped: Loss of strategic interest by the funding party. The participants' recruitment rate failed to meet the target within the pre-specified recruitment windows.)
19 Dec 2024 Planned End Date changed from 1 Jun 2025 to 31 Dec 2026.
19 Dec 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com